Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews · Breast Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 16.7%Moderate 3 · 50%High 2 · 33.3%

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Overall survival · women with early breast cancer

Taxane‐containing chemotherapy leads to lower overall survival compared with any chemotherapy without taxane (high certainty).

1 finding from 1 review

Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
HR 0.87 [0.83, 0.92]
27 studies · 39180 participants
High

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Disease‐free progression · women with early breast cancer

Taxane‐containing chemotherapy leads to lower disease‐free progression compared with any chemotherapy without taxane (high certainty).

1 finding from 1 review

Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
HR 0.88 [0.85, 0.92]
29 studies · 41909 participants
High

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Quality of life · women with early breast cancer

1 finding from 1 review

Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 7 participants
Low

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Febrile neutropenia · women with early breast cancer

Taxane‐containing chemotherapy showed no clear difference in febrile neutropenia compared with any chemotherapy without taxane (moderate certainty).

1 finding from 1 review

Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
OR 1.43 [0.89, 2.31]
23 studies · 34154 participants
Moderate

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Neuropathy (including grade 3/4 sensory or motor neuropathy, or both) · women with early breast cancer

Taxane‐containing chemotherapy probably leads to higher neuropathy (including grade 3/4 sensory or motor neuropathy, or both) compared with any chemotherapy without taxane (moderate certainty).

1 finding from 1 review

Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
OR 6.89 [3.23, 14.71]
22 studies · 31033 participants
Moderate

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Cardiotoxicity (including grade 3/4 and congestive cardiac failure) · women with early breast cancer

Taxane‐containing chemotherapy showed no clear difference in cardiotoxicity (including grade 3/4 and congestive cardiac failure) compared with any chemotherapy without taxane (moderate certainty).

1 finding from 1 review

Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
OR 0.87 [0.56, 1.33]
23 studies · 32894 participants
Moderate